Details for Patent: 11,098,015

Which drugs does patent 11,098,015 protect, and when does it expire?

Patent 11,098,015 protects COMETRIQ and CABOMETYX and is included in two NDAs.

This patent has seventy-two patent family members in twenty-six countries.

Summary for Patent: 11,098,015

Scope and claims summary:

Title:	Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxami- de, and crystalline forms thereof for the treatment of cancer
Abstract:	Disclosed are malate salts of N-(4-{[6,7-bis(methyloxy)-quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cy- clopropane-1,1-dicarboxamide, including a (L)-malate salt, a (D)-malate salt, a (DL) malate salt, and mixtures thereof; and crystalline and amorphous forms of the malate salts. Also disclosed are pharmaceutical compositions comprising at least one malate salts of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)-cy- clopropane-1,1-dicarboxamide; and methods of treating cancer comprising administering at least one malate salt of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyc- lopropane-1, 1-dicarboxamide.
Inventor(s):	Brown; Adrian St. Clair (Ely, GB), Lamb; Peter (Oakland, CA), Gallagher; William P. (Princeton, NJ)
Assignee:	Exelixis, Inc. (Alameda, CA)
Application Number:	17/171,752
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 11,098,015

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Exelixis	COMETRIQ	cabozantinib s-malate	CAPSULE;ORAL	203756-001	Nov 29, 2012		RX	Yes	No	11,098,015					METHOD OF TREATING MEDULLARY THYROID CANCER
Exelixis	COMETRIQ	cabozantinib s-malate	CAPSULE;ORAL	203756-002	Nov 29, 2012		RX	Yes	Yes	11,098,015					METHOD OF TREATING MEDULLARY THYROID CANCER
Exelixis Inc	CABOMETYX	cabozantinib s-malate	TABLET;ORAL	208692-001	Apr 25, 2016		RX	Yes	No	11,098,015					TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB
Exelixis Inc	CABOMETYX	cabozantinib s-malate	TABLET;ORAL	208692-001	Apr 25, 2016		RX	Yes	No	11,098,015					TREATMENT OF RENAL CELL CARCINOMA
Exelixis Inc	CABOMETYX	cabozantinib s-malate	TABLET;ORAL	208692-001	Apr 25, 2016		RX	Yes	No	11,098,015					TREATMENT OF ADVANCED RENAL CELL CARCINOMA
Exelixis Inc	CABOMETYX	cabozantinib s-malate	TABLET;ORAL	208692-001	Apr 25, 2016		RX	Yes	No	11,098,015					TREATMENT OF DIFFERENTIATED THYROID CANCER THAT HAS PROGRESSED FOLLOWING PRIOR VEGFR-TARGETED THERAPY

International Family Members for US Patent 11,098,015

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	075025
Australia	2010204619
Australia	2013203780
Australia	2016262732
Brazil	PI1006812
Canada	2758030